Remote Monitoring and Optimization of Heart Failure Therapy (REMODEL-HF)
Heart failure is a condition in which the heart cannot pump blood effectively, often leading to symptoms such as shortness of breath and fluid retention. After hospitalization for heart failure, patients remain at high risk of worsening symptoms, emergency visits, and hospital readmission.
This study is designed to evaluate whether using a wearable monitoring device, called the Heart Failure Management System (HFMS), can help improve the management of patients after a recent hospitalization for heart failure.
Participants in this study will be randomly assigned to one of two groups. One group will receive standard medical care alone. The other group will receive standard medical care in combination with the HFMS device. The HFMS device is worn on the body and continuously collects information such as heart rate, breathing, activity level, and signs of fluid accumulation. These data are reviewed by the clinical care team and may help detect early worsening of heart failure.
Participants will wear the device for 90 days (if assigned to the device group) and will be followed for up to one year. During the study, information will be collected on serious health events such as death, hospitalizations, emergency visits, and changes in heart failure status, as well as quality of life.
The goal of this study is to determine whether this monitoring approach can improve outcomes for patients with heart failure by enabling earlier and more effective clinical management.
연구 개요
상세 설명
The REMODEL-HF study is a prospective, multi-center, randomized, open-label clinical investigation designed to evaluate whether the use of HFMS in addition to usual care improves clinical outcomes in patients recently hospitalized for acute heart failure.
Approximately 800 participants will be enrolled and randomized in a 1:1 ratio to either: standard of care alone (control group), or standard of care plus HFMS-guided management (intervention group).
The primary objective is to determine whether HFMS-guided management results in improved overall clinical outcomes compared to usual care. Outcomes of interest include major clinical events such as cardiovascular death and heart failure hospitalization, as well as earlier indicators of clinical deterioration and changes in relevant biomarkers.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Manon Lemaire, Master
- 전화번호: +33 (0)6 33 57 18 52
- 이메일: mlemaire@zoll.com
연구 연락처 백업
- 이름: Lars Weber, PhD
- 전화번호: +49 (0) 151 611 404 98
- 이메일: lweber@zoll.com
연구 장소
-
-
-
Utrecht, 네덜란드
- UMC Utrecht
-
-
-
-
-
Giessen, 독일, 35390
- Justus-Liebig University Giessen
-
연락하다:
- Nour Katnahji, PhD
- 전화번호: +49 (0) 170 8862 141
- 이메일: nour.katnahji@zoll.com
-
수석 연구원:
- Brigit Assmus, MD
-
-
-
-
-
Uppsala, 스웨덴
- Uppsala University Hospital
-
연락하다:
- Manon Lemaire, Master
- 전화번호: +33 (0)6 33 57 18 52
- 이메일: mlemaire@zoll.com
-
-
-
-
-
Zurich, 스위스
- University Zurich
-
연락하다:
- Manon Lemaire, Master
- 전화번호: +33 (0)6 33 57 18 52
- 이메일: mlemaire@zoll.com
-
-
-
-
-
Madrid, 스페인
- Hospital Universitario 12 de Octubre
-
연락하다:
- Manon Lemaire, Master
- 전화번호: +33 (0)6 33 57 18 52
- 이메일: mlemaire@zoll.com
-
-
-
-
-
Southampton, 영국
- Southampton University Hospital NHS Foundation Trust
-
연락하다:
- Olta Ibruli, PhD
- 전화번호: +49 (0) 171 152 32 94
- 이메일: olta.ibruli@zoll.com
-
수석 연구원:
- Peter COWBURN, MD
-
-
-
-
-
Roma, 이탈리아
- Policlinico Casilino
-
연락하다:
- Manon Lemaire, Master
- 전화번호: +33 (0)6 33 57 18 52
- 이메일: mlemaire@zoll.com
-
-
-
-
-
Warsaw, 폴란드
- PIM MSWiA Hospital
-
연락하다:
- Manon Lemaire, Master
- 전화번호: +33 (0)6 33 57 18 52
- 이메일: mlemaire@zoll.com
-
수석 연구원:
- Agnieszka Pawlak, Professor
-
-
-
-
Grand Est
-
Nancy, Grand Est, 프랑스, 54000
- CHU Nancy
-
연락하다:
- Sarah Klepp, PhD
- 전화번호: +49 (0) 151 40373 869
- 이메일: sarah.klepp@zoll.com
-
수석 연구원:
- Nicolas Girerd, Professor
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age ≥18 years
- Ability and willingness to provide written informed consent and comply with study procedures
- Hospital admission for acute heart failure with dyspnea at rest and pulmonary congestion on chest X-ray, and other signs and/or symptoms of heart failure such as edema and/or positive rales on auscultation.
- All measures within 24 hours prior to randomization of systolic blood pressure ≥ 100 mmHg, and of heart rate ≥ 60 bpm.
- All measures within 24 hours prior to randomization of serum potassium ≤ 5.5 mEq/L (mmol/L).
Biomarker criteria for persistent congestion:
- NT-proBNP >1500 pg/mL at the time of admission, and;
- NT-proBNP >1000 pg/mL >=3 days after initial admission measure
- At 1 week prior to admission, either (a) ≤ ½ the optimal dose of ACEi/ARB/ARNi (see Table) prescribed, no beta-blocker prescribed, and ≤ ½ the optimal dose of MRA prescribed or (b) no ACEi/ARB/ARNi prescribed, ≤ ½ the optimal dose of beta-blocker prescribed, and ≤ ½ the optimal dose of MRA prescribed. All study participants prescribed per label and commercially fit with the HFMS device will be eligible for enrollment.
Exclusion Criteria:
- Age < 18 years
- Clearly documented intolerance to high doses (≥50% of target dose) of beta-blockers.
- Clearly documented intolerance to high doses (≥50% of target dose) of RAS blockers (both ACEi and ARB).
- Mechanical ventilation (not including CPAP/BIPAP) in the 24 hours prior to Screening.
- Significant pulmonary disease contributing substantially to the patients' dyspnea such as FEV1< 1 liter or need for chronic systemic or nonsystemic steroid therapy, or any kind of primary right heart failure such as precapillary pulmonary hypertension or chronic thromboembolic pulmonary hypertension.
- Cardiac surgery within 3 months prior to Screening
- Index Event (admission for AHF) triggered primarily by a correctable etiology such as significant arrhythmia (e.g., sustained ventricular tachycardia, or atrial fibrillation/flutter with sustained ventricular response >130 beats per minute, or bradycardia with sustained ventricular arrhythmia <45 beats per minute), severe anemia, acute coronary syndrome, pulmonary embolism, planned admission for device implantation or severe nonadherence leading to very significant fluid accumulation prior to admission and brisk diuresis after admission. Troponin elevations without other evidence of an acute coronary syndrome are not excluded.
- Uncorrected thyroid disease, active myocarditis, or known amyloid, sarcoidosis, or hypertrophic obstructive cardiomyopathy.
- History of heart transplant or on a transplant list, or using or planned to be implanted with a ventricular assist device.
- Adhesive allergy/sensitivity (e.g., acrylic adhesives).
- Compromised skin at the device application site (wound, severe dermatitis, etc.) .
- Having a prescribed wearable cardioverter defibrillator
- Pulmonary artery pressure implant (e.g. CardioMems)
- Expected survival <1 year
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: Control Group
Participants receive standard medical care for heart failure according to local clinical practice without use of the HFMS device.
|
|
|
활성 비교기: Intervention Group
Participants receive standard medical care in addition to remote monitoring using the Heart Failure Management System (HFMS).
Clinical teams review device data and may adjust treatment based on observed trends and alerts.
|
Participants assigned to the intervention group will use a noninvasive wearable physiological monitoring device (Heart Failure Management System, HFMS) designed to continuously collect data related to cardiopulmonary status, including heart rate, respiratory parameters, activity levels, and indicators of fluid status (Thoraic Fluid Index = TFI). Clinical care teams perform regular reviews of device-derived data and may respond to alerts or trends suggestive of worsening heart failure. Based on these data, the care team may adjust patient management, including modification of guideline-directed medical therapy or scheduling of follow-up assessments. The device does not deliver therapy and is used to support clinical decision-making in the outpatient management of heart failure. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Hierarchical Composite Outcome (Win Ratio)
기간: 90 days
|
A hierarchical composite outcome comparing the intervention and control groups using a win ratio approach.
The components are prioritized as follows: (1) cardiovascular death, (2) heart failure hospitalization, (3) Unplanned visit (emergency room or other emergency facilities) requiring intravenous diuretic treatment, and (4) change in NT-proBNP concentration.
Participants are compared pairwise, with outcomes evaluated sequentially according to this hierarchy.
|
90 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of Participants Achieving Target Doses of Guideline-Directed Medical Therapy (GDMT)
기간: 90 days
|
Percentage of participants reaching target doses of guideline-directed medical therapy for heart failure during the first 90 days after randomization.
|
90 days
|
|
Quality of Life Assessed by KCCQ-12
기간: Baseline, 90 days,180 days and 365 days
|
Change in health-related quality of life measured using validated questionnaire : the Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
|
Baseline, 90 days,180 days and 365 days
|
|
Time to First Clinical Event Composite
기간: Up to 365 days
|
Time to First Occurrence of Cardiovascular Death, Heart Failure Hospitalization, or Unplanned Visit Requiring Intravenous Diuretic Treatment
|
Up to 365 days
|
|
Quality of Life Assessed by EQ-5D-5L
기간: Baseline, 90 days,180 days and 365 days
|
Change in health-related quality of life measured using validated questionnaire : the EQ-5D-5L
|
Baseline, 90 days,180 days and 365 days
|
|
Hierarchical Composite Outcome (Win Ratio at 1 Year)
기간: 365 days
|
Hierarchical composite outcome using the same win ratio methodology as the primary endpoint, evaluated at 1 year.
|
365 days
|
|
Cardiovascular Death
기간: 90 days and 365 days
|
Occurrence of death due to cardiovascular causes.
|
90 days and 365 days
|
|
Heart Failure Hospitalization
기간: 90 days and 365 days
|
Occurrence of hospitalization due to heart failure.
|
90 days and 365 days
|
|
Unplanned Visit Requiring Intravenous Diuretic Treatment
기간: 90 days and 365 days
|
Occurrence of an unplanned visit requiring intravenous diuretic treatment.
Scheduled or planned intravenous diuretic treatments are not considered events.
|
90 days and 365 days
|
|
NT-proBNP Response
기간: Baseline to 90 days
|
Change in NT-proBNP concentration from baseline.
Response defined as ≥30% decrease from baseline.
|
Baseline to 90 days
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, Edwards C, Novosadova M, Takagi K, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022 Dec 3;400(10367):1938-1952. doi: 10.1016/S0140-6736(22)02076-1. Epub 2022 Nov 7.
- Boehmer JP, Cremer S, Abo-Auda WS, Stokes DR, Hadi A, McCann PJ, Burch AE, Bonderman D. Impact of a Novel Wearable Sensor on Heart Failure Rehospitalization: An Open-Label Concurrent-Control Clinical Trial. JACC Heart Fail. 2024 Dec;12(12):2011-2022. doi: 10.1016/j.jchf.2024.07.022. Epub 2024 Oct 9.
- Scholte NTB, Gurgoze MT, Aydin D, Theuns DAMJ, Manintveld OC, Ronner E, Boersma E, de Boer RA, van der Boon RMA, Brugts JJ. Telemonitoring for heart failure: a meta-analysis. Eur Heart J. 2023 Aug 14;44(31):2911-2926. doi: 10.1093/eurheartj/ehad280.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 90d0278
- 101253160 (기타 보조금/기금 번호: Granting Authority :Innovative Health Initiative Joint Undertaking (IHI JU) and Funding Program: Horizon Europe)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .